EMISPHERE TECH, (EMIS) Stock Research Free Stock Rating

Company Profile

Emisphere Technologies, Inc., a biopharmaceutical company, specializes in the oral delivery of therapeutic macromolecules and other compounds. It develops products using eligen, a proprietary oral drug delivery technology, based on the use of synthetic chemical compounds known as EMISPHERE delivery agents that enable the transport of therapeutic macromolecules, which include proteins, peptides, polysaccharides, and charged organics across biological membranes. The company’s development stage products include Oral Unfractionated Heparin, a Phase III product, and Oral Low Molecular Weight Heparin, a Phase I product, for use in the cardiovascular therapeutic area; Oral Salmon Calcitonin, a Phase II product, and Oral Recombinant Parathyroid Hormone, a Phase I product, for the treatment of osteoporosis; Partner proprietary small molecule compounds, a Phase I product, which would be used in the treatment of bone-related diseases; and Oral Recombinant Human Growth Hormone, a Phase I product, for the treatment of growth disorders. Its products in Phase I include Oral Insulin and Oral Glucagon-Like Peptides for the treatment of diabetes, and Oral Cromolyn Sodium for the treatment of asthma and allergies; and preclinical stage products consist of Oral Ciliary Neutrophic Growth Factor and Oral PYY for the treatment of obesity, and Oral Anthrax Antigen, which would be used as an anti-infective. Emisphere Technologies has collaboration agreements with Novartis Pharma AG; a license agreement with Hoffmann-La Roche, Inc. and F. Hoffmann-La Roche, LTD.; and a research and development agreement with the United States Army Medical Research Institute of Infectious Diseases. The company was founded in 1986 as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies is based in Tarrytown, New York.

Latest Headlines

Emisphere to Present At New York Society of Security Analysts 12th Annual Biotech and Specialty Pharma Conference (GlobeNewswire)

EMISPHERE TECHNOLOGIES INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or (EDGAR Online)

Emisphere Reports Receipt of Notification From NASDAQ Regarding Non-Compliance With Continued Listing Requirements (GlobeNewswire)

Looking to Sidestep the Plunge, Hedge Fund Trimmed Stakes in Q3 (Indie Research)

Hedge Fund Tracking: Timothy Barakett's Atticus Capital, Q3 2008 (at Seeking Alpha)

Emisphere Announces Study Results Of New, Orally Bioavailable Formulation of Parathyroid Hormone ('Pth') Using Eligen(r) Technology (GlobeNewswire)

EMISPHERE TECHNOLOGIES INC Financials (EDGAR Online Financials)

Emisphere to Present At Rodman & Renshaw 10th Annual Healthcare Conference (GlobeNewswire)

EMISPHERE TECHNOLOGIES INC Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial Statements (EDGAR Online)

Emisphere Technologies, Inc. Announces 2008 Third Quarter Financial Results (GlobeNewswire)